In a move that is causing a stir in the pharmaceutical world, French company Sanofi is in discussions to sell a majority 50% stake in its consumer health business, Opella, to a US private equity firm. The estimated sale is valued at a whopping 15 billion euros, making it a significant deal in the industry.
Opella, which is known for brands like the popular painkiller Doliprane, employs over 11,000 individuals and has a strong presence in the French market. The potential sale of such a substantial stake is raising eyebrows within the industry, as it could have far-reaching implications for both Sanofi and the consumer health sector as a whole.
The move comes at a time when the pharmaceutical industry is undergoing significant changes, with companies looking to streamline their operations, focus on core areas of expertise, and drive innovation. For Sanofi, this potential deal could provide the company with the resources and flexibility to pursue new avenues of growth and development.
As the negotiations progress, industry experts and stakeholders will be closely watching to see how the deal unfolds and what impact it will have on the future of Sanofi and the consumer health business. The outcome of this potential sale could have ripple effects throughout the pharmaceutical industry, shaping the landscape for years to come.
Watch the video by FRANCE 24 English
Video “Sanofi in talks to sell 50% stake in consumer health business to US private equity firm” was uploaded on 10/12/2024 to Youtube Channel FRANCE 24 English